文献速递淋巴瘤

套细胞淋巴瘤患者抗CD19 CAR-T细胞治疗失败后的结局:LYSA组织DESCAR-T研究

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
PubMed 文献 · Blood Adv · 2026-01-01

在法国DESCAR-T登记研究中,178例复发/难治套细胞淋巴瘤患者接受brexu-cel治疗,中位随访14.5个月后61例治疗失败。失败后中位OS2和PFS2分别为5.8个月和1.8个月,补救治疗总缓解率20%,双特异性T细胞衔接器组1年OS2为57%。

要点

  • brexu-cel治疗失败的套细胞淋巴瘤患者中位OS2仅5.8个月,PFS2仅1.8个月。
  • 早期失败(<3个月)患者中位OS2为1.8个月,差于3至6个月和6个月后复发者。
  • 补救治疗总缓解率20%,双特异性T细胞衔接器组1年OS2为57%,优于其他补救方案。

核心结论

  • 套细胞淋巴瘤患者brexu-cel治疗失败后结局差,双特异性抗体在该人群中可能获益。

研究设计与样本

  • 法国DESCAR-T登记研究,178例复发/难治套细胞淋巴瘤患者接受brexu-cel治疗,中位随访14.5个月后61例失败,分析失败后PFS2和OS2。

主要发现

  • 输注时36%患者MCL国际预后指数评分高,76.2%患者Ki-67指数≥30%,30.2%患者有TP53突变,31.6%患者为母细胞样变异型。
  • 失败后中位随访15个月,中位OS2为5.8个月,中位PFS2为1.8个月。
  • 早期失败(<3个月)患者中位OS2为1.8个月,3至6个月复发者为6.7个月,6个月后复发者为9个月。
  • 49例接受补救治疗:16例来那度胺联合/不联合利妥昔单抗(Len/R2),13例免疫化疗(ICT),8例布鲁顿酪氨酸激酶抑制剂联合/不联合维奈克拉(BTKi/Ven),7例双特异性T细胞衔接器(TCEs),3例其他靶向治疗,2例放疗。
  • 补救治疗后总缓解率(ORR)为20%;Len/R2和ICT组1年OS2为36%,TCEs组为57%,其他类型补救治疗组为0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Brexucabtagene autoleucel (brexu-cel) is the anti-CD19 chimeric antigen receptor CAR T-cell (CAR-T) therapy approved for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). Our study, conducted in the scope of the French DESCAR-T registry, aimed to analyze outcomes of MCL after brexu-cel failure. In the DESCAR-T registry, 178 patients with R/R MCL received brexu-cel. After a median follow-up (FU) of 14.5 months, 61 experienced failures. This study analyzes post- CAR-T failure progression-free survival (PFS2) and overall survival (OS2), according to clinical characteristics and salvage treatments. At infusion, 36% of patients had a high MCL International Prognostic Index score, 76.2% a Ki-67 index of ≥30%, 30.2% a TP53 mutation, and 31.6% a blastoid variant. After a median FU of 15 months following failure, median OS2 and PFS2 were 5.8 and 1.8 months, respectively. Patients experiencing early failure (<3 months) had a median OS2 of 1.8 months, compared with 6.7 and 9 months for those relapsing within 3 to 6 and after 6 months, respectively. Forty-nine patients received salvage therapy: 16 lenalidomide with/without rituximab (Len/R2), 13 immunochemotherapy (ICT), 8 Bruton tyrosine kinase inhibitor with/without venetoclax (BTKi/Ven), 7 bispecific T-cell engagers (TCEs), 3 another targeted therapy, and 2 received radiation. Overall, post salvage response rate (ORR) was 20%. One-year OS2 was 36% for patients treated with Len/R2 and ICT, 57% for TCEs, and 0% for other types of salvage. Notably, none of the TCE responders have relapsed to date (duration of response : 100%). Our series highlights the poor outcomes of patients with MCL after CAR-T failure and suggests a potential benefit of bispecific antibodies in this population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Aymard M, Cheminant M, Houot R, et al. Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group. Blood Adv. 2026. PMID: 41026973. doi:10.1182/bloodadvances.2025017234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。